OnCo

Create your OnCo account

One account keeps your watchlist, saved views and cancer choice in sync across your devices, and lets OnCo alert you when a trial or treatment you follow changes. No password: we email you a sign-in link.

Account creation is being switched on. Until then, press Watch on any page and your list stays in this browser.

Cancers & treatments·Sequencing

KIT exon 11-mutant GIST: lines of therapy

Cancer page →

4 standard-of-care settings across 3 lines and 2 biomarker subgroups. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.

LineAll comersRisk group
Early / localised11
Advanced, first line1·
Second line1·

Early / localised

SubgroupSettingApproachProducts and trialsEvidence
All comersLocalised, resectableComplete surgical resection without lymphadenectomy; laparoscopic for smaller gastric tumours; neoadjuvant imatinib for large or poorly placed tumours.
ImatinibRobotic & minimally invasive surgeryKIT
78
Risk groupAfter resection, high riskThree years of adjuvant imatinib 400 mg (SSG XVIII); trials of longer courses.
ImatinibKIT
78

Advanced, first line

SubgroupSettingApproachProducts and trialsEvidence
All comersMetastatic, first lineImatinib 400 mg continued until progression, with CT response assessment by Choi criteria.
ImatinibCT (computed tomography)KIT
78

Second line

SubgroupSettingApproachProducts and trialsEvidence
All comersProgression on imatinibDose escalation to 800 mg, then sunitinib, regorafenib and ripretinib, ideally guided by the secondary mutation on circulating tumour DNA.
ImatinibSunitinibRegorafenibRipretinibLiquid biopsy (ctDNA)Circulating tumour DNA (ctDNA)
90

Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.